LA 213

Drug Profile

LA 213

Alternative Names: LA 233

Latest Information Update: 01 Nov 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lacer
  • Class Antihypertensives; Antithrombotics
  • Mechanism of Action Platelet activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hypertension; Thrombosis

Most Recent Events

  • 07 Jun 2001 Profile reviewed but no significant changes made
  • 01 Nov 2000 Discontinued - Preclinical for Hypertension in Spain (unspecified route)
  • 01 Nov 2000 Discontinued - Preclinical for Thrombosis in Spain (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top